Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Articles published by Femasys Inc.

< Previous 1 2 Next >
Femasys Announces Financial Results for Quarter Ended September 30, 2024, and Provides Corporate Update
From Femasys Inc.
Via GlobeNewswire
Tickers FEMY
Femasys to Exhibit at the Annual AAGL 2024 Global Conference
From Femasys Inc.
Via GlobeNewswire
Tickers FEMY
Femasys Announces Issued U.S. Patent Covering FemBloc® Device for Female Permanent Birth Control
From Femasys Inc.
Via GlobeNewswire
Tickers FEMY
Femasys Announces Partnership with Boston IVF, Prominent Network of Fertility Centers, to Offer FemaSeed
From Femasys Inc.
Via GlobeNewswire
Tickers FEMY
Femasys to Exhibit at ASRM 2024 and Participate in the Congress’ KEEPR Education Program
From Femasys Inc.
Via GlobeNewswire
Tickers FEMY
Femasys to Participate in a Fireside Chat at the 2024 Maxim Healthcare Virtual Summit
From Femasys Inc.
Via GlobeNewswire
Tickers FEMY
Femasys Receives Second Order from Spain Partners After Successfully Completing Commercial FemaSeed® Infertility Treatments
From Femasys Inc.
Via GlobeNewswire
Tickers FEMY
Femasys Announces Infertility Clinic Customers from Coast to Coast
From Femasys Inc.
Via GlobeNewswire
Tickers FEMY
Femasys Secures Strategic Distribution Partnerships for Commercialization of FemaSeed® for over $1.3M in Spanish Market
From Femasys Inc.
Via GlobeNewswire
Tickers FEMY
Femasys Inc. Receives U.S. FDA Clearance to Market FemChec®, an Innovative Diagnostic Solution for Fallopian Tube Check
From Femasys Inc.
Via GlobeNewswire
Tickers FEMY
Femasys to Exhibit at The Canadian Fertility and Andrology Society’s 70th Annual Meeting
From Femasys Inc.
Via GlobeNewswire
Tickers FEMY
Femasys to Participate in Fireside Chat at the H.C. Wainwright 26th Annual Global Investment Conference
From Femasys Inc.
Via GlobeNewswire
Tickers FEMY
Femasys Announces CE Mark and Canadian Approval for FemVue® MINI, a Fallopian Tube Assessment Solution
From Femasys Inc.
Via GlobeNewswire
Tickers FEMY
Femasys Hosts Congresswoman Lucy McBath at Georgia Headquarters
From Femasys Inc.
Via GlobeNewswire
Tickers FEMY
Femasys Announces Financial Results for Quarter Ended June 30, 2024 and Provides Corporate Update
From Femasys Inc.
Via GlobeNewswire
Tickers FEMY
Femasys to Participate in European Society of Human Reproduction and Embryology 40th Annual Meeting in Amsterdam
From Femasys Inc.
Via GlobeNewswire
Tickers FEMY
Femasys Receives CE Mark Approval for Four of its Women’s Health Products Clearing the Path for the Company to Begin Commercialization Efforts in Europe
From Femasys Inc.
Via GlobeNewswire
Tickers FEMY
Femasys CEO and Founder Kathy Lee-Sepsick Meets with the White House’s Office of Science and Technology Policy to Discuss the Cancer Moonshot Initiative
From Femasys Inc.
Via GlobeNewswire
Tickers FEMY
Femasys CEO and Founder Kathy Lee-Sepsick Meets with the White House’s Gender Policy Council
From Femasys Inc.
Via GlobeNewswire
Tickers FEMY
Femasys Announces Financial Results for Quarter Ended March 31, 2024 and Provides Corporate Update
From Femasys Inc.
Via GlobeNewswire
Tickers FEMY
Femasys Expands Commercial Management Team with Addition of Experienced New Hires
From Femasys Inc.
Via GlobeNewswire
Tickers FEMY
Femasys CEO and Founder Kathy Lee-Sepsick Meets with Members of Congress to Raise Awareness of the Company and Discuss Women’s Healthcare Initiatives
From Femasys Inc.
Via GlobeNewswire
Tickers FEMY
Femasys Announces Financial Results for Year Ended December 31, 2023 and Provides Corporate Update
From Femasys Inc.
Via GlobeNewswire
Tickers FEMY
Femasys Invites Investors to View Fireside Chat Today, March 21, 2024, to Discuss the Infertility Treatment Landscape
From Femasys Inc.
Via GlobeNewswire
Tickers FEMY
Femasys Announces Positive Topline Data from Pivotal Trial for its FDA-Cleared FemaSeed® for the Treatment of Infertility
From Femasys Inc.
Via GlobeNewswire
Tickers FEMY
Femasys to Participate in Fireside Chat to Discuss the Infertility Treatment Landscape on March 21, 2024
From Femasys Inc.
Via GlobeNewswire
Tickers FEMY
Femasys Completes the First In-Office Commercial Procedure with the FDA-Cleared FemaSeed Infertility Solution
From Femasys Inc.
Via GlobeNewswire
Tickers FEMY
Femasys’ FemaSeed FDA Clearance Brings Timely Access to a First-Line Infertility Treatment Option as an Alternative to IVF
From Femasys Inc.
Via GlobeNewswire
Tickers FEMY
Femasys Inc. Advances Commercial Readiness with Appointment of Richard Spector to New Position of Chief Commercial Officer
From Femasys Inc.
Via GlobeNewswire
Tickers FEMY
Femasys Inc. Begins FemBloc Pivotal Trial Enrollment at UC Davis Medical Center, a Hub for Innovation and Groundbreaking Research in Health Care for Women
From Femasys Inc.
Via GlobeNewswire
Tickers FEMY
< Previous 1 2 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.